Asprosin in Breast Cancer

N/ANot Yet RecruitingNCT06592560

Marina Hanna Thabet Ghobrial84 enrolled

Overview

To evaluate the clinical utility of Asprosin measurement in breast cancer patients in comparison with healthy controls and patients with benign breast lesions. To compare between Asprosin and the routine markers (CEA, CA15-3) as biomarkers for breast cancer diagnosis

Study Type

OBSERVATIONAL

Enrollment

Conditions

Breast Cancer

Interventions

ELISADEVICE

Specific test: Assay of asprosin marker will be measured by enzyme-linked immunosorbent assay ( ELISA).

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- Females aged (40 ± 20 years) who did not receive any chemotherapy or surgical treatment and they will be divided as follow: Group 1: healthy controls from healthy volunteers. Group 2: patients with benign breast lesions. Group 3: breast cancer patients. Exclusion Criteria: * 1- Female patients with any other type of malignant or benign tumors. 2- Past history of chemotherapy or surgical treatment of cancer.

Outcomes

Primary Outcomes

Diagnostic value of Asprosin as a biomarker in breast cancer

Evaluation of the clinical utility of measurement of asprosin as a non invasive biomarker in the diagnosis of breast cancer

Time frame: Baseline

Secondary Outcomes

Diagnostic value of Asprosin as a biomarker in breast cancer

Comparing asproin and the routine markers (CEA, CA15-3) as biomarkers for diagnosis of breast cancer.

Time frame: Baseline

Central Contacts

Marina Hanna Thabet

CONTACT

01007970949 hannamarina626@gmail.com

Eman Mohamed Abdelrahman

CONTACT

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.